Pharmacoeconomics and macular degeneration

Abstract

Pharmacoeconomics is assuming an increasingly important role with regard to whether drugs are listed on the drug formulary of a country or province. It has been estimated that the application of standardized, value-based medicine drug analyses can save over 35% from a public healthcare insurer drug formulary while maintaining or improving patient care.

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

“…Another economic evaluation that is often used consists of conducting a cost-utility assessment that uses "utility" scores (preference assessment) to generate Quality Adjusted Life Years (QALYs) as a potential synthetic assessment indicator [23,24]. Raftery et al [25] have carried out a cost-utility model assessing the cost per QALY over 10 years of bevacizumab versus ranibizumab.…”